Noboru Nakaigawa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5854897/publications.pdf

Version: 2024-02-01

36 1,548 18 37
papers citations h-index g-index

43 43 43 1921 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene, 1999, 18, 2343-2350.	5.9	487
2	Oncogenic Mutants of RON and MET Receptor Tyrosine Kinases Cause Activation of the \hat{l}^2 -Catenin Pathway. Molecular and Cellular Biology, 2001, 21, 5857-5868.	2.3	155
3	Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through Hypoxia-inducible factor. Oncogene, 2003, 22, 2728-2738.	5.9	97
4	Inactivation of von Hippel-Lindau Gene Induces Constitutive Phosphorylation of MET Protein in Clear Cell Renal Carcinoma. Cancer Research, 2006, 66, 3699-3705.	0.9	89
5	Impact of maximum Standardized Uptake Value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report. BMC Cancer, 2010, 10, 667.	2.6	89
6	Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course. BMC Cancer, 2012, 12, 162.	2.6	68
7	FDG PET/CT as a prognostic biomarker in the era of molecular-targeting therapies: max SUVmax predicts survival of patients with advanced renal cell carcinoma. BMC Cancer, 2016, 16, 67.	2.6	54
8	Neutrophil-to-lymphocyte ratio predicts prostatic carcinoma in men undergoing needle biopsy. Oncotarget, 2015, 6, 32169-32176.	1.8	53
9	Neutrophil-to-lymphocyte ratio is a prognostic marker in bladder cancer patients after radical cystectomy. BMC Cancer, 2016, 16, 185.	2.6	46
10	A low psoas muscle volume correlates with a longer hospitalization after radical cystectomy. BMC Urology, 2017, 17, 87.	1.4	40
11	PD-1 and PD-L1 are more highly expressed in high-grade bladder cancer than in low-grade cases: PD-L1 might function as a mediator of stage progression in bladder cancer. BMC Urology, 2018, 18, 97.	1.4	36
12	Evaluation of Response to Multikinase Inhibitor in Metastatic Renal Cell Carcinoma by FDG PET/Contrast-Enhanced CT. Clinical Nuclear Medicine, 2010, 35, 918-923.	1.3	30
13	Essential content of evidenceâ€based clinical practice guidelines for bladder cancer: The Japanese Urological Association 2015 update. International Journal of Urology, 2016, 23, 640-645.	1.0	30
14	The early response of renal cell carcinoma to tyrosine kinase inhibitors evaluated by FDG PET/CT was not influenced by metastatic organ. BMC Cancer, 2014, 14, 390.	2.6	26
15	A Low Psoas Muscle Index before Treatment Can Predict a Poorer Prognosis in Advanced Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy. BioMed Research International, 2017, 2017, 1-4.	1.9	25
16	The acceleration of glucose accumulation in renal cell carcinoma assessed by FDG PET/CT demonstrated acquisition of resistance to tyrosine kinase inhibitor therapy. BMC Cancer, 2017, 17, 39.	2.6	24
17	Early assessment with 18F-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography to predict short-term outcome in clear cell renal carcinoma treated with nivolumab. BMC Cancer, 2019, 19, 298.	2.6	24
18	C-reactive protein in patients with advanced metastatic renal cell carcinoma: Usefulness in identifying patients most likely to benefit from initial nephrectomy. BMC Cancer, 2012, 12, 337.	2.6	20

#	Article	IF	Citations
19	One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survival. Cancer Chemotherapy and Pharmacology, 2017, 79, 855-861.	2.3	16
20	Outcomes of treatment for localized prostate cancer in a single institution: comparison of radical prostatectomy and radiation therapy by propensity score matching analysis. World Journal of Urology, 2020, 38, 2477-2484.	2.2	16
21	FDG PET/CT after first molecular targeted therapy predicts survival of patients with renal cell carcinoma. Cancer Chemotherapy and Pharmacology, 2018, 81, 739-744.	2.3	15
22	Time-dependent change in relapse sites of renal cell carcinoma after curative surgery. Clinical and Experimental Metastasis, 2018, 35, 69-75.	3.3	15
23	BHD-associated kidney cancer exhibits unique molecular characteristics and a wide variety of variants in chromatin remodeling genes. Human Molecular Genetics, 2018, 27, 2712-2724.	2.9	14
24	Pretreatment Neutrophil-to-Lymphocyte Ratio Can Predict the Prognosis in Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy. BioMed Research International, 2016, 2016, 1-5.	1.9	11
25	Renal Cell Carcinoma in a Horseshoe Kidney Treated with Laparoscopic Partial Nephrectomy. Case Reports in Oncological Medicine, 2018, 2018, 1-3.	0.3	11
26	Improvement on parenchymal suturing technique in laparoscopic partial nephrectomy. International Journal of Urology, 2008, 15, 854-855.	1.0	10
27	C-reactive protein at 1Âmonth after treatment of nivolumab as a predictive marker of efficacy in advanced renal cell carcinoma. Cancer Chemotherapy and Pharmacology, 2020, 86, 75-85.	2.3	10
28	A Multicentre Retrospective Study of Nivolumab Plus Ipilimumab for Untreated Metastatic Renal Cell Carcinoma. Anticancer Research, 2021, 41, 6199-6209.	1.1	7
29	Correlation of urinary loss rate after catheter removal and longâ€term urinary continence after robotâ€assisted laparoscopic radical prostatectomy. International Journal of Urology, 2021, 28, 440-443.	1.0	6
30	A pooled analysis of the efficacy and safety of cabozantinib post immunotherapy in patients with advanced renal cell carcinoma Journal of Clinical Oncology, 2020, 38, 5089-5089.	1.6	5
31	Histopathological analysis of aggressive renal cell carcinoma harboring a unique germline mutation in fumarate hydratase. Pathology International, 2018, 68, 473-478.	1.3	4
32	The Pretherapeutic Neutrophil-to-Lymphocyte Ratio for Docetaxel-Based Chemotherapy Is Useful for Predicting the Prognosis of Japanese Patients with Castration-Resistant Prostate Cancer. BioMed Research International, 2019, 2019, 1-5.	1.9	4
33	Development of a Microfluidic Device to Form a Long Chemical Gradient in a Tissue from Both Ends with an Analysis of Its Appearance and Content. Micromachines, 2021, 12, 1482.	2.9	3
34	Complete Response to Sorafenib Rechallenge in a Patient with Metastatic Renal Cell Carcinoma. Case Reports in Oncological Medicine, 2017, 2017, 1-3.	0.3	2
35	Roughness of the renal tumor surface could predict the surgical difficulty of robotâ€assisted partial nephrectomy. Asian Journal of Endoscopic Surgery, 2022, 15, 591-598.	0.9	2
36	Urological Cancer. , 2021, , 77-93.		0